Verified· 2 sources

LamKap Bio beta AG

Summary

About the company

LamKap Bio beta AG researches, develops and manufactures fully human bispecific antibodies for the treatment of solid tumors. Its pipeline includes molecules designed to selectively block CD47 on tumor cells and bispecifics that retarget immune effector cells such as macrophages, T cells and natural killer cells.

AI-generated

Offering

Products & services

Industry:Research & Development

✓ Offered3

Outbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub

LamKap Bio beta AG

About the company

Products & services

Looking for direct email addresses and phone numbers?

LamKap Bio beta AG

About the company

Products & services

Looking for direct email addresses and phone numbers?

No knowledge articles yet

LamKap Bio beta AG in comparison

Industry comparisons are coming soon

Similar companies